Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.54 |
| ▸ | ITK | Q08881 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 5/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.51 |
| ▸ | CDK9 | P50750 | 4/20 | 0.51 |
| ▸ | SIK1 | P57059 | 2/20 | 0.51 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.51 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.49 |
| ▸ | CCNH | P51946 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12952346 | 0.93 | EGFR (0.55) | EGFRITKBTKJAK2JAK1 | |
| SCHEMBL5105140 | 0.90 | BRD4 (0.61) | EGFRITKBTKJAK2JAK1 | |
| SCHEMBL5096075 | 0.89 | EGFR (0.50) | EGFRITKBTKJAK2JAK1 | |
| SCHEMBL3495111 | 0.87 | EGFR (0.61) | EGFRITKBTKJAK2JAK1 | |
| SCHEMBL3495504 | 0.87 | EGFR (0.56) | EGFRITKBTKJAK2JAK3 | |
| SCHEMBL5098343 | 0.86 | EGFR (0.52) | EGFRITKBTKJAK2JAK1 | |
| SCHEMBL5098344 | 0.86 | EGFR (0.52) | EGFRITKBTKJAK2JAK1 | |
| SCHEMBL3497282 | 0.85 | SYK (0.54) | EGFRITKBTKJAK3CDK2 | |
| SCHEMBL5104881 | 0.85 | ALK (0.55) | EGFRITKBTKCDK2CCNT1 | |
| SCHEMBL3496601 | 0.85 | ALK (0.52) | EGFRITKBTKJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452879-B2 | N4-(1-tert-Butoxycarbonylazetidin-3-yl)-5-fluoro-N2-(4-morpholinophenyl)-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for IgE (\"Fc epsilon RI\") and IgG (\"Fc gamma RI\") antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | EGFR 1181/4885ITK 1065/4885BTK 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.